Children

ddI (didanosine, Videx / VidexEC) is safe and effective for use in children aged two weeks and over.[1][2][3]

In 2008, the US FDA approved the use of Videx EC delayed-release caplets to include children weighing at least 20 kilograms. In children 20 to <25 kg, 200mg once daily is advised. Children weighing 25 to <60 should take 250mg once daily.

For patients weighing less than 20 kilograms, the recommended dose of didanosine powder for oral solution is based on age and body surface area:

  • patients aged 2 weeks to 8 months should receive 100 mg/m2 twice daily.
  • patients older than 8 months should receive 120 mg/m2 twice daily. One study has found that half of this dose may be appropriate for children under four months of age.[4]

The oral solution of ddI contains antacids and may effect the metabolism of other drugs being used.

In all patients with renal impairment, dosing interval and dosing reductions should be made according to the manufacturer's prescribing information.

Stavudine (d4T) used with ddI may produce enhanced toxicity and is not advised unless the potential benefit outweighs the risk. Adverse events could include pancreatitis and peripheral neuropathy. If d4T is co-administered with tenofovir, it can be taken with a light meal.

Donate